Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Recruiting
Observational Study
Myelofibrosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 55 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 650 (estimated)
- Sponsor
- Center for International Blood and Marrow Transplant Research · Research network
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMT…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients fulfilling the following criteria will be eligible for inclusion in the study:
* PMF, post-ET MF, or post-PV MF.
* Int-2 or high-risk disease as determined by the DIPSS.
* Age ≥55 at the time of DIPSS assessment.
* For the alloHCT arm:
* Donors must be a…
Contacts